Tech Company Financing Transactions
OverT Bio Funding Round
On 5/6/2024, OverT Bio raised $16 million in Seed financing from ARTIS Ventures, Wing Venture Capital and Alexandria Venture Investments.
Transaction Overview
Company Name
Announced On
5/6/2024
Transaction Type
Venture Equity
Amount
$16,000,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to expand discovery platforms focused on addressing the primary barriers for cell therapy, leading to durable and curative treatments for advanced solid tumors.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
430 E 29th St
New York, NY 10016
USA
New York, NY 10016
USA
Phone
Undisclosed
Website
Email Address
Overview
OverT Bio is developing effective and safe cellular therapies for solid tumors. Founded in 2022 by Dr. Mat Legut and Dr. Neville Sanjana, OverT has pioneered new pooled functional screening and synthetic genomics platforms (OverTarget� and OverTCR�) to develop next-generation engineered immune cells.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Co-Founder
Mat Legut
Co-Founder
Neville Sanjana
Browse more venture capital transactions:
Prev: 5/6/2024: Allegria Therapeutics venture capital transaction
Next: 5/6/2024: Zanskar venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs